Isolpharm

Gamma camera imaging experiment at LENA

In May 2025 the WP3 of the ADMIRAL experiment performed a characterization test of the gamma camera using Ag-111 produced at LENA, Pavia. For the first time a mouse phantom[…]

FisMat 2025 – ISOL technique for the production of medical radionuclides

We are proud to announce that the ISOLPHARM group will arrange a thematic workshop entitled ISOL technique for the production of medical radionuclides at the FisMat 2025 conference, which will[…]

ISOLPHARM 2024 annual meeting

On December 12th, the ISOLPHARM 2024 annual meeting took place at the Legnaro National Laboratories of INFN. The Work Packages of the ADMIRAL and ISOLPHARM_CORE experiments showed their latest results[…]

A Large Collaboration Between Universities and Research Centers

The ISOLPHARM Project was born from the collaboration between the Departments of Pharmaceutical and Pharmacological, Department of Chemical Sciences of the University of Padova and the Legnaro National Laboratories (LNL) of the National Institute of Nuclear Physics (INFN) where the Selective Production of Exotic Specie (SPES) project in under development. By means, of Isotope Separation On-Line technique both traditional and innovative radioisotopes will be produced with high-specific activity, going beyond the state-of-art of the radioisotope production.

Strengths and key features

The key features of ISOLPHARM are: a) the presence of a strong local collaboration between INFN-LNL, INFN-PD, INFN-PV, TIFPA, UNIPD and UNIBS in many fields of research, ranging from the production of the RIBs to the employment of the radionuclides. b) the ISOL technique, which can easily provide high specific activity radionuclides. c) the INFN patent, which proves the innovation and excellence of the project. d) the low environmental and social impact, since nuclear reactors are not used for the provision of the radionuclides, which traditionally may be obtained irradiating massive amount of materials, that lately become tons of nuclear wastes.